January 18, 2022 BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patients with Advanced Parkinson’s DiseaseRead more
SPECIALIZED PRESS January 17, 2022 Not intended for U.S. and UK MediaAnnual Bayer Pharma Media Day 2022Read more
January 12, 2022 Bayer invites global researchers to submit novel crop protection compounds through new Testing4Ag programRead more
January 10, 2022 Bayer and Mammoth Biosciences to collaborate on novel gene editing technologyRead more
January 6, 2022 BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson’s DiseaseRead more
SPECIALIZED PRESS December 21, 2021 Not intended for U.S. and UK MediaU.S. FDA approves Xarelto™ to treat venous thromboembolism (VTE) and to prevent VTE in childrenRead more
SPECIALIZED PRESS December 17, 2021 Not intended for U.S. and UK MediaBayer receives positive CHMP opinion for finerenone as a new treatment for adult patients with chronic kidney disease associated with type 2 diabetesRead more
December 8, 2021 Bayer to launch Project Carbonview, an industry-first digital carbon footprint measurement solution for agricultureRead more
SPECIALIZED PRESS December 3, 2021 Not intended for U.S. and UK MediaPhase III trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancerRead more
December 1, 2021 Bayer Invests €100 million in Sustainable Health Products to Advance Company’s 2030 Sustainability CommitmentsRead more
